Update on MED2002

Futura Medical PLC 09 May 2006 For immediate release 9 May 2006 Futura Medical plc Update on MED2002 Futura Medical plc (AIM: FUM), the pharmaceutical drug and medical device group that develops innovative products for sexual health, announces that it has been advised by the major global pharmaceutical group (MGPG) that the formal approval process is in its final stage. James Barder, Futura's Chief Executive, said: 'We are informed by MGPG that MED2002 remains a high priority for them.' For further information: Futura Medical plc James Barder, Chief Executive Tel: +44 (0) 1483 845 670 mail to: james.barder@futuramedical.co.uk www.futuramedical.co.uk Media enquiries: Buchanan Communications Mark Court Tel: +44 (0) 20 7466 5000 Futura Medical plc Futura Medical is an AIM-listed pharmaceutical drug and medical device group developing innovative products for sexual health. The Company is developing a portfolio of products with the intention of licensing their manufacture and distribution to major pharmaceutical and healthcare groups. Exclusive worldwide distribution agreements have already been signed in respect of Futura's two condom safety products, CSD500 and FLD500, with SSL International plc, the makers of DurexTM condoms. Futura's primary focus is on Over the Counter (OTC) products with particular appeal to men and women who are reluctant to discuss potentially embarrassing sexual matters with their doctors. For further information please visit: www.futuramedical.co.uk This information is provided by RNS The company news service from the London Stock Exchange